Literature DB >> 12734707

Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Joachim Wachtlin1, Tim Behme, Heinrich Heimann, Ulrich Kellner, Michael H Foerster.   

Abstract

PURPOSE: To report a case with concentric retinal pigment epithelium (RPE) atrophy after a single photodynamic therapy (PDT).
METHODS: We report a case of a 33-year-old female patient who developed RPE atrophy after a single standard PDT for treatment of a juxtafoveal, predominantly classic choroidal neovascularization (CNV).
RESULTS: After a single PDT treatment, visual acuity increased from 20/50 to 20/20. Six weeks after PDT, a concentric area of RPE atrophy was clearly visible on fluorescein angiogram. This circular area corresponded to the 3500 microm diameter of the laser spot used in the PDT treatment. The visual acuity and the RPE atrophy remained stable over the follow-up period of 3 years.
CONCLUSIONS: We are unable to explain the exact mechanism of the observed RPE changes; however, they did not lead to loss of visual acuity. Different reasons for the RPE atrophy such as collateral damage of the choriocapillaris with a subsequent secondary RPE atrophy, a direct photochemical effect due to the early localization of the photosensitizer in the RPE, or a depigmentation or photobleaching of the RPE, which led to a window defect in the fluorescein angiogram without loss of the major functional properties of the RPE, are possible mechanisms involved in the development of the documented lesion.

Entities:  

Mesh:

Year:  2003        PMID: 12734707     DOI: 10.1007/s00417-003-0650-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  6 in total

1.  Histopathological changes following photodynamic therapy in human eyes.

Authors:  Ursula Schmidt-Erfurth; Horst Laqua; Ursula Schlötzer-Schrehard; Arne Viestenz; Gottfried O H Naumann
Journal:  Arch Ophthalmol       Date:  2002-06

2.  Problems with and pitfalls of photodynamic therapy.

Authors:  G A Peyman; A A Kazi; M Unal; B Khoobehi; S Yoneya; K Mori; D M Moshfeghi
Journal:  Ophthalmology       Date:  2000-01       Impact factor: 12.079

3.  Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye.

Authors:  R Haimovici; M Kramer; J W Miller; T Hasan; T J Flotte; K T Schomacker; E S Gragoudas
Journal:  Curr Eye Res       Date:  1997-02       Impact factor: 2.424

4.  Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin.

Authors:  J W Miller; A W Walsh; M Kramer; T Hasan; N Michaud; T J Flotte; R Haimovici; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1995-06

5.  Vascular targeting in photodynamic occlusion of subretinal vessels.

Authors:  U Schmidt-Erfurth; T Hasan; E Gragoudas; N Michaud; T J Flotte; R Birngruber
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

6.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

  6 in total
  24 in total

1.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

2.  [Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results].

Authors:  J Wachtlin; A Wehner; H Heimann; M H Foerster
Journal:  Ophthalmologe       Date:  2004-05       Impact factor: 1.059

3.  The effect of digital measurement software on photodynamic therapy.

Authors:  Siamak Ansari-Shahrezaei; Erdem Ergun; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-17       Impact factor: 3.117

4.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

5.  Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases.

Authors:  Beatrix Feigl; Brian Brown; Jan Lovie-Kitchin; Lawrence Lee
Journal:  Doc Ophthalmol       Date:  2006-03-06       Impact factor: 2.379

6.  Pigment epithelial changes with abnormal fundus autofluorescence after photodynamic therapy for idiopathic choroidal neovascularization.

Authors:  Taku Wakabayashi; Fumi Gomi; Miki Sawa; Kunihiko Shiraki; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

7.  Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  H Imai; S Honda; Y Nakanishi; H Yamamoto; Y Tsukahara; A Negi
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

8.  Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting.

Authors:  Danny Siu-Chun Ng; Alvin Kwan-Ho Kwok; Justin Man-Kit Tong; Clement Wai-Nang Chan; Walton Wai-Tat Li
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

9.  Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Mamdouh M Kabeel; Ashraf M El-Batarny; Mohamed K Tameesh; Moustafa A Abou El Enein
Journal:  Clin Ophthalmol       Date:  2008-03

10.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.

Authors:  W-M Chan; T Y Y Lai; A L Wong; J-P Tong; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.